Drug intelligence / Profile preview

paracetamol + codeine + caffeine

Development stage
Unknown
Lead developer
Steiner & Co.
Modality
Small Molecules
Administration
Oral
01

Overview

Azur compositum is a fixed-dose combination analgesic drug developed by Steiner & Co. Deutsche Arzneimittelgesellschaft. It is composed of three active ingredients: paracetamol (acetaminophen), codeine phosphate, and caffeine. Paracetamol acts as a non-opioid analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system and blocking cyclooxygenase (COX) enzymes. Codeine is a selective mu-opioid receptor agonist that alters the perception of pain and the emotional response to pain. Caffeine is included as a central nervous system stimulant that potentiates the analgesic effects of paracetamol and codeine, potentially by increasing their absorption or through its own adenosine receptor antagonism. The drug is indicated for the treatment of mild to moderate pain, particularly postoperative dental pain following procedures such as third molar surgery.

Brand names
Azur compositum
Other names
paracetamol + codeine phosphate + caffeineacetaminophen + codeine + caffeine
02

Targets

ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)MOR (Mu opioid receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on paracetamol + codeine + caffeine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + codeine + caffeine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call